医学
德诺苏马布
关节骨
中止
骨质疏松症
骨密度保护剂
绝经后骨质疏松症
绝经后妇女
内科学
重症监护医学
骨密度
骨矿物
作者
Yannick Degboé,Guillaume Couture
出处
期刊:Joint Bone Spine
[Elsevier BV]
日期:2025-08-28
卷期号:93 (2): 105954-105954
被引量:2
标识
DOI:10.1016/j.jbspin.2025.105954
摘要
Discontinuation of denosumab in postmenopausal osteoporosis causes a rebound phenomenon with a rapid increase in bone turnover markers and accelerated bone loss, often within 6-12 months. Without an appropriate relay therapy, up-to 10% of the patients experience multiple vertebral fractures. This phenomenon is linked to a multifactorial dysregulation of bone remodelling. In 2021, the European Calcified Tissue Society (ECTS) proposed guidelines for discontinuing denosumab in patients with postmenopausal osteoporosis. Our review covers the latest research on risk stratification for rebound phenomenon, the various relay treatment options based on risk levels, and the recommended follow-up for these patients. Post-denosumab treatment is important. Bisphosphonates therapy and regular monitoring of serum CTX (crosslaps) represent the cornerstone of the management of rebound phenomenon following denosumab discontinuation in postmenopausal osteoporosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI